title: Early administration of verapamil after thrombolysis in acute anterior myocardial infarction. Effect on left ventricular remodeling and clinical outcome. VAMI Study Group. Verapamil Acute Myocardial Infarction.
abstract: BACKGROUND
  The administration of verapamil during the reperfusion phase of acute myocardial infarction can reduce the extent and severity of microvessel damage and limit myocardial dysfunction. We aimed at investigating the effect of early verapamil administration on left ventricular remodeling and the clinical evolution after myocardial infarction.
  
  
  METHODS
  Eighty-eight patients with first acute anterior myocardial infarction thrombolysed < 4 hours from symptom onset were enrolled in a multicenter, randomized, double-blind, controlled study of verapamil administration (5 mg i.v. + 2 microg/kg/min over 24 hours). Echocardiographic end-diastolic (EDV) and end-systolic (ESV) left ventricular volumes were assessed by biplane Simpson's rule.
  
  
  RESULTS
  At 90 days, EDV in the verapamil and placebo groups was respectively 88.9 +/- 27.8 and 95.8 +/- 30.7 ml (p = 0.11), ESV was 52.6 +/- 22.7 and 57.7 +/- 25.4 ml (p = 0.18). There was no change over time in the verapamil group (day 3 vs day 90: EDV 85.0 +/- 17.7 vs 88.9 +/- 27.8 ml, p = NS; ESV 48.7 +/- 14.1 vs 52.6 +/- 22.7 ml, p = NS) while left ventricular volume increased in the placebo group (day 3 vs day 90: EDV 87.6 +/- 21.1 vs 95.8 +/- 30.7 ml, p = 0.03; ESV 52.0 +/- 16.9 vs 57.7 +/- 25.4 ml, p = 0.08). NYHA functional classes were differently distributed at 30 and 90 days (chi2 = 0.009 and 0.07), with a lower prevalence of classes II and III in the verapamil group (p = 0.03).
  
  
  CONCLUSIONS
  The early intravenous administration of verapamil in thrombolysed patients can reduce left ventricular remodeling and NYHA functional class after acute anterior myocardial infarction.
authors.affiliation: Department of Clinical Metodology and Medico-Surgical Technology, University of Bari, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Marangelli
authors.forename: C
authors.initials: C
authors.lastname: Memmola
authors.forename: M S
authors.initials: MS
authors.lastname: Brigiani
authors.forename: L
authors.initials: L
authors.lastname: Boni
authors.forename: M G
authors.initials: MG
authors.lastname: Biasco
authors.forename: D
authors.initials: D
authors.lastname: Scrutinio
authors.forename: S
authors.initials: S
authors.lastname: Iliceto
authors.forename: P
authors.initials: P
authors.lastname: Rizzon
mesh_terms: D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D004311:Double-Blind Method; D004452:Echocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control; D015912:Thrombolytic Therapy; D020257:Ventricular Remodeling / Q000187:drug effects*; D014700:Verapamil / Q000008:administration & dosage*
chemical_list: D002121:Calcium Channel Blockers; D014700:Verapamil